Emmaus Life Sciences (EMMA) Price & Analysis

Q: What was Emmaus Life Sciences Inc’s price range in the past 12 months?

Emmaus Life Sciences Inc lowest stock price was <$0.01 and its highest was $0.05 in the past 12 months.

Q: What is Emmaus Life Sciences Inc’s market cap?

Emmaus Life Sciences Inc’s market cap is $830.25K.

Q: When is Emmaus Life Sciences Inc’s upcoming earnings report date?

Emmaus Life Sciences Inc’s upcoming earnings report date is Aug 18, 2025 which is in 6 days.

Q: How were Emmaus Life Sciences Inc’s earnings last quarter?

Emmaus Life Sciences Inc released its earnings results on May 15, 2025. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.04.

Q: Is Emmaus Life Sciences Inc overvalued?

According to Wall Street analysts Emmaus Life Sciences Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Emmaus Life Sciences Inc pay dividends?

Emmaus Life Sciences Inc does not currently pay dividends.

Q: What is Emmaus Life Sciences Inc’s EPS estimate?

Emmaus Life Sciences Inc’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Emmaus Life Sciences Inc have?

Emmaus Life Sciences Inc has 63,865,570 shares outstanding.

Q: What happened to Emmaus Life Sciences Inc’s price movement after its last earnings report?

Emmaus Life Sciences Inc reported an EPS of -$0.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Q: Which hedge fund is a major shareholder of Emmaus Life Sciences Inc?

Currently, no hedge funds are holding shares in EMMA

Compare

89 Followers

EMMA Stock Chart & Stats

Day’s Range― - ―

52-Week Range<$0.01 - $0.05

Previous CloseN/A

Volume11.42K

Average Volume (3M)11.28K

Market Cap

$830.25K

Enterprise Value$32.28M

Total Cash (Recent Filing)$1.33M

Total Debt (Recent Filing)$32.98M

Price to Earnings (P/E)―

Beta54.57

Next Earnings

Aug 18, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding63,865,570

10 Day Avg. Volume16,540

30 Day Avg. Volume11,283

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap38.88

Enterprise Value/Revenue1.95

Enterprise Value/Gross Profit2.10

Enterprise Value/Ebitda69.57

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering1

Emmaus Life Sciences News

Emmaus Life Sciences Appoints Hiroko Huynh as New CAO

Emmaus Life Sciences ( ($EMMA) ) just unveiled an update. On June 30, 2025, Yasushi Nagasaki resigned as...

1M ago

EMMA

Emmaus Life Sciences receives FDA approval for Endari label changes

Emmaus Life Sciences (EMMA) has received Food and Drug Administration approval for changes to the labelling of Endari...

2M ago

EMMA

Emmaus Life Sciences Delays Annual Report Filing

Emmaus Life Sciences ( ($EMMA) ) has released a notification of late filing. Emmaus Life Sciences, Inc. has...

4M ago

EMMA

Pfizer withdrawal of Oxbryta raises questions, sends Fulcrum stock higher

Pfizer ( ...

11M ago

NVS

PFE

Leerink sees little impact to genetic medicines from Pfizer’s Oxbryta withdrawal

Leerink analyst David Risinger notes that Pfizer ( ...

11M ago

PFE

BEAM

Emmaus Life Sciences appoints Willis Lee as CEO

Emmaus Life Sciences announced that Willis Lee has been appointed as CEO. Mr. Lee, who previously served as...

1y ago

EMMA

Emmaus receives ‘No Action Indicated’ inspection classification from FDA

Emmaus Life Sciences announced receiving the “No Action Indicated” classification following a routine inspection by the United States...

1y ago

EMMA

Emmaus gets marketing authorization for SCD treatment Endari in Oman

Emmaus Life Sciences announced that it has received marketing authorization from the Oman Ministry of Health for the...

2y ago

EMMA

EMMA FAQ

What was Emmaus Life Sciences Inc’s price range in the past 12 months?

Emmaus Life Sciences Inc lowest stock price was <$0.01 and its highest was $0.05 in the past 12 months.

What is Emmaus Life Sciences Inc’s market cap?

Emmaus Life Sciences Inc’s market cap is $830.25K.

When is Emmaus Life Sciences Inc’s upcoming earnings report date?

Emmaus Life Sciences Inc’s upcoming earnings report date is Aug 18, 2025 which is in 6 days.

How were Emmaus Life Sciences Inc’s earnings last quarter?

Emmaus Life Sciences Inc released its earnings results on May 15, 2025. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.04.

Is Emmaus Life Sciences Inc overvalued?

According to Wall Street analysts Emmaus Life Sciences Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Emmaus Life Sciences Inc pay dividends?

Emmaus Life Sciences Inc does not currently pay dividends.

What is Emmaus Life Sciences Inc’s EPS estimate?

Emmaus Life Sciences Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Emmaus Life Sciences Inc have?

Emmaus Life Sciences Inc has 63,865,570 shares outstanding.

What happened to Emmaus Life Sciences Inc’s price movement after its last earnings report?

Emmaus Life Sciences Inc reported an EPS of -$0.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Emmaus Life Sciences Inc?

Currently, no hedge funds are holding shares in EMMA

Company Description

Emmaus Life Sciences Inc

Emmaus Life Sciences, Inc. is a biotechnology company focused on the development and commercialization of innovative therapies for rare diseases. The company primarily targets sickle cell disease and other hematologic disorders, offering its lead product, Endari, which is an FDA-approved treatment aimed at reducing the frequency of painful crises associated with sickle cell disease. Emmaus operates within the biotechnology sector, leveraging its expertise in drug development and patient care to improve the quality of life for individuals affected by these conditions.

Emmaus Life Sciences (EMMA) Earnings & Revenues

Historic Earnings Reports

EMMA Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"NaN":"―"}},"plotLines":[{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[null,null,null,null,null],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2019","6":"Nov<br/>2024","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.02,0.018461538461538463,0.016923076923076923,0.015384615384615385,0.013846153846153847,0.012307692307692308,0.01076923076923077,0.009230769230769232,0.007692307692307693,0.006153846153846154,0.004615384615384615,0.003076923076923078,0.0015384615384615406,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.26,"date":1548979200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1554076800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1556668800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1561939200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1567296000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1569888000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.04,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.01,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >